SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/07/22 Y-mAbs Therapeutics, Inc. 10-Q 9/30/22 88:8.4M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 2.23M 2: EX-10.1 Material Contract HTML 97K 3: EX-10.2 Material Contract HTML 97K 4: EX-10.3 Material Contract HTML 156K 5: EX-31.1 Certification -- §302 - SOA'02 HTML 30K 6: EX-31.2 Certification -- §302 - SOA'02 HTML 30K 7: EX-32.1 Certification -- §906 - SOA'02 HTML 26K 8: EX-32.2 Certification -- §906 - SOA'02 HTML 26K 14: R1 Document and Entity Information HTML 77K 15: R2 Consolidated Balance Sheets HTML 119K 16: R3 Consolidated Balance Sheets (Parenthetical) HTML 39K 17: R4 Consolidated Statements of Net Income (Loss) and HTML 96K Comprehensive Income (Loss) 18: R5 Consolidated Statements of Changes in HTML 99K Stockholders' Equity 19: R6 Consolidated Statements of Cash Flows HTML 97K 20: R7 Organization and Description of Business HTML 27K 21: R8 Basis of Presentation HTML 32K 22: R9 Summary of Significant Accounting Policies HTML 85K 23: R10 Product Revenue HTML 58K 24: R11 Net Loss Per Share HTML 50K 25: R12 Inventories HTML 59K 26: R13 Intangible Assets, Net HTML 27K 27: R14 Accrued Liabilities HTML 44K 28: R15 License Agreements and Commitments HTML 159K 29: R16 Stockholders' Equity HTML 36K 30: R17 Share-Based Compensation HTML 99K 31: R18 Related Party Transactions HTML 28K 32: R19 Income Taxes HTML 30K 33: R20 Other Benefits HTML 26K 34: R21 Gain From Sale of Priority Review Voucher HTML 27K 35: R22 Subsequent Events HTML 27K 36: R23 Summary of Significant Accounting Policies HTML 110K (Policies) 37: R24 Summary of Significant Accounting Policies HTML 61K (Tables) 38: R25 Product Revenue (Tables) HTML 52K 39: R26 Net Loss Per Share (Tables) HTML 48K 40: R27 Inventories (Tables) HTML 58K 41: R28 Accrued Liabilities (Tables) HTML 44K 42: R29 License Agreements and Commitments (Tables) HTML 148K 43: R30 Share-Based Compensation (Tables) HTML 86K 44: R31 BASIS OF PRESENTATION - Accumulated deficit HTML 27K (Details) 45: R32 BASIS OF PRESENTATION - Secondary public offering HTML 37K (Details) 46: R33 BASIS OF PRESENTATION - Cash and cash equivalents HTML 26K (Details) 47: R34 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 32K Concentration of Credit Risk (Details) 48: R35 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 25K Inventory (Details) 49: R36 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 41K Value Measurement (Details) 50: R37 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 25K Revenue Recognition - Product revenue (Details) 51: R38 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 42K Revenue Recognition - License revenue (Details) 52: R39 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 26K Segment (Details) 53: R40 PRODUCT REVENUE - Discounts and Allowances HTML 70K (Details) 54: R41 PRODUCT REVENUE - Concentrations (Details) HTML 36K 55: R42 NET LOSS PER SHARE - Basic and diluted (Details) HTML 45K 56: R43 NET LOSS PER SHARE - Anti-dilutive securities HTML 26K (Details) 57: R44 Inventories (Details) HTML 48K 58: R45 Intangible Assets, Net (Details) HTML 43K 59: R46 Accrued Liabilities (Details) HTML 37K 60: R47 LICENSE AGREEMENTS AND COMMITMENTS - License HTML 69K Agreements (Details) 61: R48 LICENSE AGREEMENTS AND COMMITMENTS - Other HTML 43K agreements (Details) 62: R49 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 65K agreements (Details) 63: R50 LICENSE AGREEMENTS AND COMMITMENTS - Lease costs HTML 34K (Details) 64: R51 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 43K maturities (Details) 65: R52 LICENSE AGREEMENTS AND COMMITMENTS - Lease term HTML 28K and discount rate (Details) 66: R53 LICENSE AGREEMENTS AND COMMITMENTS - Severance HTML 31K Related Benefits (Details) 67: R54 LICENSE AGREEMENTS AND COMMITMENTS - Legal matters HTML 29K (Details) 68: R55 STOCKHOLDERS' EQUITY - Authorized, Common and HTML 43K Preferred Stock (Details) 69: R56 STOCKHOLDERS' EQUITY - Stock grant agreements with HTML 73K non-employees (Details) 70: R57 STOCKHOLDERS' EQUITY - Issuance of common stock HTML 38K (Details) 71: R58 SHARE-BASED COMPENSATION - 2015 Plan (Details) HTML 29K 72: R59 SHARE-BASED COMPENSATION - 2018 Plan (Details) HTML 48K 73: R60 SHARE-BASED COMPENSATION - Stock-based HTML 35K compensation expense - Options (Details) 74: R61 SHARE-BASED COMPENSATION - Stock option activity HTML 65K (Details) 75: R62 SHARE-BASED COMPENSATION - Stock option grants HTML 62K (Details) 76: R63 SHARE-BASED COMPENSATION - Stock option HTML 31K unrecognized compensation (Details) 77: R64 SHARE-BASED COMPENSATION - Restricted Stock Unit HTML 63K Activity (Details) 78: R65 Related Party Transactions (Details) HTML 38K 79: R66 INCOME TAXES - Loss before income taxes (Details) HTML 35K 80: R67 INCOME TAXES - Uncertain tax positions (Details) HTML 25K 81: R68 Other Benefits (Details) HTML 31K 82: R69 Gain From Sale of Priority Review Voucher HTML 36K (Details) 83: R70 Subsequent Events (Details) HTML 28K 86: XML IDEA XML File -- Filing Summary XML 156K 84: XML XBRL Instance -- ymab-20220930x10q_htm XML 1.76M 85: EXCEL IDEA Workbook of Financial Reports XLSX 144K 10: EX-101.CAL XBRL Calculations -- ymab-20220930_cal XML 139K 11: EX-101.DEF XBRL Definitions -- ymab-20220930_def XML 610K 12: EX-101.LAB XBRL Labels -- ymab-20220930_lab XML 1.24M 13: EX-101.PRE XBRL Presentations -- ymab-20220930_pre XML 949K 9: EX-101.SCH XBRL Schema -- ymab-20220930 XSD 196K 87: JSON XBRL Instance as JSON Data -- MetaLinks 373± 572K 88: ZIP XBRL Zipped Folder -- 0001558370-22-016659-xbrl Zip 508K
SEPARATION AGREEMENT AND GENERAL RELEASE
This Separation Agreement and General Release (the “Agreement”) is made and entered into by and between Y-mAbs Therapeutics, Inc. (the “Company”), located at 230 Park Avenue, Suite 3350, New York, NY 10169, and its employee, Claus Juan Møller San Pedro (“Employee”), who resides at [***].
WHEREAS, Employee has been employed by the Company as Chief Executive Officer since March 1, 2016 under the terms of a Service Agreement, dated January 3, 2016 (“Service Agreement”); and
WHEREAS, in consideration for Employee’s execution of this Agreement and other consideration set forth herein, the Company shall treat Employee’s termination as one “without cause” under the Service Agreement and the Company’s 2015 and 2018 Equity Incentive Plans; and
WHEREAS, the parties have reached certain mutual agreements and understandings with respect to the termination of Employee’s employment with the Company, and desire to settle fully and finally any claims, disputes and obligations relating to Employee’s employment with the Company and the termination thereof.
NOW, THEREFORE, IT IS HEREBY AGREED THAT:
1
2
In consideration of the compensation and benefits set forth herein, the receipt and adequacy of which are hereby acknowledged by Employee, Employee hereby releases and discharges the Company, and each of its respective present, former and future affiliates and related companies, as well as the shareholders, directors, trustees, officers, employees, attorneys, thereof,
3
and all their heirs, successors, assigns, and agents (collectively, the “Company Releasees”), from any and all claims, causes of action, suits, debts, controversies, judgments, decrees, damages, liabilities, covenants, contracts and agreements, whether known or unknown, in law or equity, whether statutory or common law, whether federal, state, local or otherwise, including, but not limited to, any claims relating to, or arising out of any aspect of Employee’s employment with the Company, or the termination of such employment, including without limitation:
To the extent any claim is not releasable, Employee acknowledges that the payments and consideration received hereunder more than offset any monetary sums owing to Employee from any non-releasable claim. Nothing herein shall be construed to prohibit Employee from exercising Employee’s rights as specified in Paragraph 15(c) or shall prevent Employee from enforcing the terms of this Agreement.
4
5
6
Pursuant to Paragraph 6.2 of the Service Agreement, during the Notice Period, Employee will receive compensation equal to the taxable value of Employee’s returned mobile phone and laptop in the amount of ($429/12) $36 per month.
7
for five (5) years following the Notice Period, and the Company shall not restrict the Employee from reporting any such claim directly to the insurer.
8
[Signature Page Follows]
9
IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives as of the date first indicated above.
Y-MABS THERAPEUTICS, INC. By:_/s/ Thomas Gad ________________ Name: Thomas Gad Title: Founder, President, Interim Chief Executive Officer and Head of Business Development & Strategy | By:_/s/ Claus Juan Møller San Pedro _____ Name:Claus Juan Møller San Pedro |
[Signature Page to Claus Juan Møller San Pedro Severance Agreement]
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 11/7/22 | 8-K | ||
For Period end: | 9/30/22 | |||
8/24/22 | ||||
5/31/22 | 8-K | |||
4/24/22 | ||||
2/5/18 | ||||
3/1/16 | ||||
1/3/16 | ||||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/29/24 Y-mAbs Therapeutics, Inc. S-8 2/29/24 4:185K Toppan Merrill Bridge/FA 2/29/24 Y-mAbs Therapeutics, Inc. 10-K 12/31/23 101:10M Toppan Merrill Bridge/FA 3/30/23 Y-mAbs Therapeutics, Inc. S-8 3/30/23 4:168K Toppan Merrill Bridge/FA 3/30/23 Y-mAbs Therapeutics, Inc. 10-K 12/31/22 106:10M Toppan Merrill Bridge/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/26/18 Y-mAbs Therapeutics, Inc. 8-K:5,7,9 9/25/18 4:284K Toppan Merrill/FA |